Literature DB >> 23389933

Comparison of galactomannan enzyme immunoassay performance levels when testing serum and plasma samples.

P Lewis White1, Tim Jones, Katie Whittle, Joanne Watkins, Rosemary A Barnes.   

Abstract

Diagnostic galactomannan (GM) enzyme immunoassay (EIA) testing is formally validated only for serum, though in practice, plasma is occasionally tested. It is assumed, but not confirmed, that results will be comparable to those for serum. GM EIA when testing plasma was evaluated, providing sensitivity (85.7%) and specificity (85.4%) comparable to those for serum. Plasma index values were higher than those for serum; if plasma GM EIA were used to define probable cases, four additional cases would have been diagnosed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23389933      PMCID： PMC3623416          DOI： 10.1128/CVI.00730-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  5 in total

1.  Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies.

Authors:  Marcio Nucci; Simone Aranha Nouér; Monica Grazziutti; Naveen Sanath Kumar; Bart Barlogie; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2010-10-29       Impact factor: 9.079

2.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

3.  Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients.

Authors:  R A Barnes; P L White; C Bygrave; N Evans; B Healy; J Kell
Journal:  J Clin Pathol       Date:  2009-01       Impact factor: 3.411

Review 4.  Galactomannan detection for invasive aspergillosis in immunocompromized patients.

Authors:  Mariska M Leeflang; Yvette J Debets-Ossenkopp; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Patrick Mm Bossuyt; Christina M Vandenbroucke-Grauls
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

5.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079
  5 in total
  7 in total

1.  Comparison of Performance Characteristics of Aspergillus PCR in Testing a Range of Blood-Based Samples in Accordance with International Methodological Recommendations.

Authors:  Jan Springer; P Lewis White; Shanna Hamilton; Denise Michel; Rosemary A Barnes; Hermann Einsele; Juergen Löffler
Journal:  J Clin Microbiol       Date:  2016-01-06       Impact factor: 5.948

Review 2.  Galactomannan detection for invasive aspergillosis in immunocompromised patients.

Authors:  Mariska M G Leeflang; Yvette J Debets-Ossenkopp; Junfeng Wang; Caroline E Visser; Rob J P M Scholten; Lotty Hooft; Henk A Bijlmer; Johannes B Reitsma; Mingming Zhang; Patrick M M Bossuyt; Christina M Vandenbroucke-Grauls
Journal:  Cochrane Database Syst Rev       Date:  2015-12-30

3.  Analytical Comparison of In Vitro-Spiked Human Serum and Plasma for PCR-Based Detection of Aspergillus fumigatus DNA: a Study by the European Aspergillus PCR Initiative.

Authors:  Juergen Loeffler; Carlo Mengoli; Jan Springer; Stéphane Bretagne; Manuel Cuenca-Estrella; Lena Klingspor; Katrien Lagrou; Willem J G Melchers; C Oliver Morton; Rosemary A Barnes; J Peter Donnelly; P Lewis White
Journal:  J Clin Microbiol       Date:  2015-06-17       Impact factor: 5.948

4.  Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative.

Authors:  P Lewis White; Rosemary A Barnes; Jan Springer; Lena Klingspor; Manuel Cuenca-Estrella; C Oliver Morton; Katrien Lagrou; Stéphane Bretagne; Willem J G Melchers; Carlo Mengoli; J Peter Donnelly; Werner J Heinz; Juergen Loeffler
Journal:  J Clin Microbiol       Date:  2015-06-17       Impact factor: 5.948

5.  Novel mouse monoclonal antibodies specifically recognize Aspergillus fumigatus galactomannan.

Authors:  Andrey L Matveev; Vadim B Krylov; Ljudmila A Emelyanova; Arsenii S Solovev; Yana A Khlusevich; Ivan K Baykov; Thierry Fontaine; Jean-Paul Latgé; Nina V Tikunova; Nikolay E Nifantiev
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

Review 6.  Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.

Authors:  Toine Mercier; Ellen Guldentops; Katrien Lagrou; Johan Maertens
Journal:  Front Microbiol       Date:  2018-04-04       Impact factor: 5.640

7.  Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model.

Authors:  P Lewis White; Nathan P Wiederhold; Juergen Loeffler; Laura K Najvar; Willem Melchers; Monica Herrera; Stephane Bretagne; Brian Wickes; William R Kirkpatrick; Rosemary A Barnes; J Peter Donnelly; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.